Autologous anti-CD19-transduced CD3+ cells (Tecartus®). HTA ID: 21005

Assessment Status Rapid Review Complete
HTA ID 21005
Drug Autologous anti-CD19-transduced CD3+ cells
Brand Tecartus®
Indication For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.  
Assessment Process
Rapid review commissioned 03/03/2021
Rapid review completed 22/03/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of autologous anti-CD19-transduced CD3+ cells compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 31/03/2021

The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.